

Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas

Francesca Marciello · Carolina Di Somma · Michela Del Prete · Vincenzo Marotta · Valeria Ramundo · Annachiara Carratù · Chiara de Luca di Roseto · Luigi Camera · Annamaria Colao · Antongiulio Faggiano

Received: 3 September 2013 / Accepted: 4 December 2013 / Published online: 3 January 2014
© Springer Science+Business Media New York 2013

Abstract Multiple endocrine neoplasia type 1 (MEN1) is a hereditary syndrome associated with the development of many endocrine tumors, involving mainly pituitary, parathyroids, pancreas, although a proliferative state interests all neuroendocrine system. MEN1 pancreatic neuroendocrine tumors (pNETs) are multiples and can secrete different hormones. The therapeutic approach is based on surgery which usually is followed by tumor relapse or persistence unless to be highly aggressive. Biotherapy with somatostatin analogs and dopamine agonists could be of great benefit to manage these patients without altering their life quality. We report a case of a 36-year-old MEN1 man affected with multicentric pNETs associated with insulinoma syndrome. Therapy with symptomatic agents (diazoxide), as well as biotherapy (lanreotide, cabergoline) was started. At 6-month follow-up, symptomatic agents were stopped and disease control was only based on lanreotide plus cabergoline. This combined biotherapy was able to control endocrine syndromes and tumor growth.

Subsequently, a safer and selective surgical intervention on pNETs was performed. An excellent response to therapy with lanreotide autogel and cabergoline has been observed in a MEN1 patient with pNETs associated with insulinoma syndrome. The potential synergistic effects of lanreotide autogel and cabergoline on insulin-secreting neuroendocrine tumors are discussed.

Keywords Insulinoma syndrome · MEN1 syndrome · Neuroendocrine tumors · Somatostatin analogs · Dopamine agonists

Introduction

Multiple endocrine neoplasia type 1 (MEN1) is a hereditary syndrome predisposing to the development of many endocrine and neuroendocrine tumors (NETs) and/or hyperplasia, involving mainly pituitary, parathyroids, and pancreas [1]. In these patients, prognosis is mainly related to the behavior of tumors arising from pancreas [2]. Pancreatic NET (pNET) arising from islet cells may be non-functioning or functioning, with production of active hormones such as gastrin, insulin, vasoactive intestinal polypeptide, glucagon, and somatostatin [3]. Therapeutic approach in pNETs is based on surgery. However, in MEN1 there is a high risk of recurrence even after radical surgery and a considerable risk of morbidity and mortality associated with the surgical management [4, 5].

Somatostatin analogs (SSAs) have been demonstrated to induce symptomatic, biochemical, and antiproliferative effects in well-differentiated NETs [6, 7]. Unfortunately, neither sub-cutaneous nor long-acting slow release SSAs resulted in high rate of clinical and biochemical response in patients with insulin-secreting pNETs [8, 9]. Furthermore,

F. Marciello (✉) · M. Del Prete · V. Marotta · V. Ramundo · A. Carratù · C. de Luca di Roseto · A. Colao
Division of Endocrinology, Department of Clinical Medicine and Surgery, University of Naples “Federico II”, Naples, Italy
e-mail: francesca.marciello@libero.it; afaggian@unina.it; francescamarciello81@gmail.com

C. Di Somma
IRCCS SDN Foundation of Naples, Naples, Italy

L. Camera
Department Biomorphological and Functional Sciences,
University of Naples “Federico II”, Naples, Italy

A. Faggiano
Endocrinology, Department of Diagnostic Imaging and Radiotherapy, Istituto Nazionale Tumori “Fondazione G.Pascale” - IRCCS Naples, Naples, Italy




Fig. 1 Hormonal markers of insulinoma (serum glycaemia, insulin, and C-peptide) before and 3, 6, and 12 months after the beginning of treatment. Lanreotide treatment was started at basal, while cabergoline was started at 3 month

response duration is variable and side effects such as a paradoxical impairment of hypoglycemia, due to predominant suppression of contra-regulator hormones, may occur [9, 10].

Dopamine agonists (DAs) are effective in controlling tumor growth and hormone secretion in pituitary tumors. DA activity in NETs is hypothesized on the basis of reported expression of dopamine receptors (DR2) in these tumors. Possible synergistic effects of SSAs and DAs could be of great benefit to manage MEN1-related pNETs, either arresting tumor growth or maintaining their unaltered quality of life.

In this case report, we describe a MEN1 man affected by multiple insulin-secreting and nonfunctioning pNETs experiencing an excellent response to the treatment with lanreotide autogel, a long-acting formulation of SSA. Since a concomitant therapy with cabergoline was given for a prolactin (PRL)-secreting pituitary adenoma, the potential synergistic effects of lanreotide autogel and cabergoline on insulinoma are discussed.

Case presentation

A 36-year-old man presented with symptoms of neuroglycopenia. Physical examination revealed sweating and tachycardia. Biochemical assessment showed hypoglycemia and not suppressed insulin and C-peptide levels (Fig. 1). Fasting test confirmed the clinical diagnosis of insulinoma by revealing an insulin to glycaemia ratio of 0.6 and C-peptide serum concentrations of 6.0 ng/ml in condition of hypoglycemia. To localize the insulin-secreting primary tumor, a contrast-enhanced helical computed tomography (CT) was performed and detected 4 nodules ranging 10–25 mm along head, body, and tail of the pancreas. A complete hormonal and instrumental work-up was performed to characterize the pNETs and to screen for a MEN1 syndrome. High plasma levels of chromogranin A (not shown) and gastrin (>150 pmol/l) were found and associated, at the endoscopy, to an erosive gastro-duodenitis. A pituitary microadenoma was

detected by magnetic resonance imaging and characterized by PRL hypersecretion (>3,000 mU/l), while primary hyperparathyroidism (PTH = 15.8 pmol/l) with a mild increase of serum calcium levels (2.6 mmol/l) was associated to a left inferior parathyroid adenoma at cervical Doppler ultrasonography and sestamibi SPECT scintigraphy. A whole body Indium-¹¹¹-DTPA-Phe1-octreotide scintigraphy (Octreoscan) pointed out a strong uptake corresponding to the greatest pancreatic lesion.

The diagnosis of insulinoma syndrome, Zollinger–Ellison syndrome, microprolactinoma, and primary hyperparathyroidism was made. This picture was consistent with the diagnosis of MEN1 syndrome. To confirm the diagnosis of MEN1, germline mutation in the *menin* gene was searched as previously described [11]. A novel heterozygote frameshift 335delA mutation in the exon 2 was revealed in this patient.

In order to control the Zollinger–Ellison syndrome, proton pump inhibitor (omeprazole) was prescribed (20 mg twice a day) followed by a rapid improvement of gastric symptoms. One week later, diazoxide (300 mg a day in 3 daily doses) and lanreotide (slow release formulation, 30 mg every 2 weeks) were introduced in the schedule treatment, in order to improve symptoms related to hyperinsulinemia the former and to inhibit gastrin and insulin hypersecretion the latter. A high hydration regimen plus hydrochlorothiazide (25 mg a day) was recommended to achieve normocalcemia. During the first 3 months of therapy, a decrease of frequency and severity of hypoglycemic events occurred. At the 3-month hormonal follow-up, normalization of gastrin (<25 pmol/l), as well as marked decrease of C-peptide (Fig. 1) with normalization of the insulin to glycaemia ratio was observed. No side effects were observed. Therefore, omeprazole treatment was stopped, diazoxide treatment was lowered (150 mg a day divided in 3 daily doses) and lanreotide was given at the dose of 60 mg every 4 weeks. Due to the progressive increase of PRL levels (>4,000 mU/l), a cabergoline schedule treatment was started. At 6-month follow-up, a stable normalization of gastrin levels, a further

decrease of insulin and C-peptide (Fig. 1) and a suppression of PRL levels were observed, allowing to stop diazoxide and to decrease cabergoline doses. At this time, lanreotide autogel 120 mg every 8 weeks was started in place of lanreotide 60 mg every 4 weeks. This hormonal picture remains unchanged at the 12-month follow-up (Fig. 1). These results paralleled the complete disappearance of hypoglycemic events and gastrointestinal disorders. A morphological evaluation of the pNETs was performed 1 year after the beginning of the treatment: compared to basal CT scan, the nodules were stable in size and number. Contrast enhancement of the pNETs, which was high and rapid at baseline, was then scarce after medical therapy.

Due to the complete and stable normalization of symptomatology, as well as the possibility to completely remove pNETs, the patient underwent distal pancreatectomy, tumor enucleation in the pancreatic head and duodenum and locoregional lymph node dissection. Histology and immunohistochemistry for chromogranin A and synaptophysin highlighted a diagnosis of well-differentiated pNET (G1) in a total of 16 nodules (size ranging 3–22 mm). Two insulin-positive pNETs were found in pancreas, while a gastrin-positive tumor was found in duodenum. All lymph nodes were unaffected.

After surgery, the patient recovered rapidly and was discharged without any therapy but cabergoline. Both basal and secretin-stimulated pancreatic hormone values were normal, and neither clinical symptoms nor tumor recurrence was after a 5 year follow-up.

Discussion

Surgery represents the treatment of choice for MEN1-related pNETs with significant benefits in terms of survival. However, this approach for small tumors is still controversial because pNETs < 2 cm seem to have a more indolent behavior. In particular, pNET surgery in MEN1 is associated with a higher risk of complications and mortality, as well as a high rate of recurrence [5].

SSAs represent the gold standard in the treatment of functioning NETs [9]. The PROMID study demonstrated also that octreotide LAR has antiproliferative effects in patients with metastatic NETs of midgut, significantly improving the time to progression as compared to placebo [7]. However, in insulin-secreting pNET, SSAs seem to difficultly control hormone secretion and proliferating activity [12]. In fact, even if SSAs inhibit insulin secretion and activity [13, 14], the SSA-induced inhibition of contra-regulatory hormones (glucagon, GH, and IGF-1) may be higher than insulin suppression, resulting in scarce effectiveness in the improvement of hypoglycemia [15]. The inadequate control of insulin secretion by SSAs is likely a

consequence of the low expression of SSTR2 and SSTR5 in insulin-secreting pNET, which also explains the low percentage of Octreoscan-positive tumors.

In the current case, a MEN1 patient with multiple pNETs associated with Zollinger–Ellison and insulinoma syndrome, after an initial clinical improvement on SSA, experienced a complete and stable clinical remission on SSA and DA therapy. At CT scan, pNETs were stable, while contrast enhancement was decreased revealing decreased tumor activity [16]. These findings could be imputable to the combined use of biotherapy with SSA and DA, even if it is difficult to exclude that only one of the two drugs was active. In this regard, it was previously reported in literature a case of a patient affected by prolactinoma and metastatic islet cell tumor secreting pancreatic polypeptide (PP), where DAs caused a decrease in PP levels and inhibited liver metastases [17]. Double-staining experiments showed that D2 colocalized with insulin-containing secretory granules and quinpirole, a D2-like receptor agonist, was able to inhibit glucose-stimulated insulin secretion, suggesting a potential implication of D2 on this activity [18]. Besides, it has been demonstrated that D2 are expressed in NET associated with ectopic ACTH syndrome and that cabergoline may be effective in controlling cortisol excess in a subgroup of these patients [19]. In NETs, D2 is frequently expressed in low- and intermediate-grade tumors, but it is to underlined that, in the majority of cases, it is coexpressed with SSTR2 and SSTR5 [20–22]. However, the *in vivo* efficacy of DA has not well-established yet in NET [22]. In the last years, basic research observations on the interaction of SSTR and DR2, and clinical reports of efficacy of combined SST and DA treatment in pituitary adenomas [23, 24], lead to the concept of creating chimeric molecules combining structural features of both compound classes. SSTR/DR2 chimeric compounds have recently been investigated also in NETs resulting in decreased cell viability in human midgut NET cells [25].

In conclusions, a combined therapy with SSA and DA was associated with complete normalization of a hyperinsulinemic hypoglycemia syndrome and tumor stabilization in a patient with MEN1 pNETs. In patients with insulinoma, particularly if associated with MEN1, SSA, and DA should be taken in account not only to normalize the functional syndrome but also to induce antitumoral effects.

Conflict of interest None.

References

1. M.L. Brandi, R.F. Gagel, A. Angeli, J.P. Bilezikian, P. Beck-Peccoz, C. Bordi, B. Conte-Devolx, A. Falchetti, R.G. Gheri, A.

- Libroia, C.J. Lips, G. Lombardi, M. Mannelli, F. Pacini, B.A. Ponder, F. Raue, B. Skogseid, G. Tamburrano, R.V. Thakker, N.W. Thompson, P. Tommasetti, F. Tonelli, S.A. Wells Jr, S.J. Marx, Guidelines for diagnosis and therapy of MEN type 1 and type 2. *J. Clin. Endocrinol. Metab.* **86**, 5658–5671 (2001)
2. P. Goudet, A. Murat, C. Biquet, C. Cardot-Bauters, A. Costa, P. Ruzsniowski, P. Niccoli, F. Ménégau, G. Chabrier, F. Borson-Chazot, A. Tabarin, P. Bouchard, B. Delemer, A. Beckers, C. Bonithon-Kopp, Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. *World J. Surg.* **34**, 249–255 (2010)
 3. A. Calender, G. Cadiot, M. Mignon, Multiple endocrine neoplasia type 1: genetic and clinical aspects. *Gastroenterol. Clin. Biol.* **25**, B38–B48 (2001)
 4. F. Tonelli, F. Giudici, G. Fratini, M.L. Brandi, Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature. *Endocr. Pract.* **17**, 33–40 (2011)
 5. R.T. Jensen, G. Cadiot, M.L. Brandi, W.W. de Herder, G. Kaltsas, P. Komminoth, J.Y. Scoazec, R. Salazar, A. Sauvanet, R. Kianmanesh, Barcelona consensus conference participants: ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. *Neuroendocrinology* **95**, 98–119 (2012)
 6. P. Ferolla, A. Faggiano, F. Grimaldi, D. Ferone, G. Scarpelli, V. Ramundo, R. Severino, M.C. Bellucci, L.M. Camera, G. Lombardi, G. Angeletti, A. Colao, Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. *J. Endocrinol. Invest.* **35**, 326–331 (2012)
 7. A. Rinke, H.H. Müller, C. Schade-Brittinger, K.J. Klose, P. Barth, M. Wied, C. Mayer, B. Aminossadati, U.F. Pape, M. Bläker, J. Harder, C. Arnold, T. Gress, R. Arnold, PROMID Study Group: placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J. Clin. Oncol.* **27**, 4656–4663 (2009)
 8. P.N. Maton, J.D. Gardner, R.T. Jensen, Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. *Dig. Dis. Sci.* **34**, 28S–39S (1989)
 9. B. Eriksson, K. Oberg, Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. *Ann. Oncol.* **10**(Suppl 2), S31–S38 (1999)
 10. B. Eriksson, J. Renstrup, H. Imam, K. Oberg, High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. *Ann. Oncology.* **8**, 1041–1044 (1997)
 11. V. Nuzzo, L. Tauchmanová, A. Falchetti, A. Faggiano, F. Marini, S. Piantadosi, M.L. Brandi, L. Leopaldi, A. Colao, MEN1 family with a novel frameshift mutation. *J. Endocrinol. Invest.* **29**, 450–456 (2006)
 12. C. Scarpignato, I. Pelosini, Somatostatin analogs for cancer treatment and diagnosis: an overview. *Chemotherapy* **47**, 1–29 (2001)
 13. H. Kishikawa, Y. Okada, A. Hirose, T. Tanikawa, K. Kanda, Y. Tanaka, Successful treatment of insulinoma by a single daily dose of octreotide in two elderly female patients. *Endocr. J.* **53**, 79–85 (2006)
 14. T. Katabami, H. Kato, N. Shirai, S. Naito, N. Saito, Successful long-term treatment with once-daily injection of low-dose octreotide in an aged patient with insulinoma. *Endocr. J.* **52**, 629–634 (2005)
 15. C. Scarpignato, The place of octreotide in the medical management of the dumping syndrome. *Digestion* **57**, 114–118 (1996)
 16. D. Bensimhon, P. Soyer, J.P. Brouland, M. Boudiaf, Y. Fargeaudou, R. Rymer, Gastrointestinal stromal tumors: role of computed tomography before and after treatment. *Gastroenterol. Clin. Biol.* **32**, 91–97 (2008)
 17. R.D. Pathak, T.H. Tran, A.L. Bursshell, A case of dopamine agonists inhibiting pancreatic polypeptide secretion from an islet cell tumor. *J. Clin. Endocrinol. Metab.* **89**, 581–584 (2004)
 18. B. Rubí, S. Ljubcic, S. Pournourmohammadi, S. Carobbio, M. Armanet, C. Bartley, P. Maechler, Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. *J. Biol. Chem.* **280**, 36824–36832 (2005)
 19. R. Pivonello, D. Ferone, W.W. de Herder, A. Faggiano, L. Bodei, R.R. de Krijger, G. Lombardi, A. Colao, S.W. Lamberts, L.J. Hofland, Dopamine receptor expression and function in corticotroph ectopic tumors. *J. Clin. Endocrinol. Metab.* **92**, 65–69 (2007)
 20. D. O'Toole, A. Saveanu, A. Couvelard, G. Gunz, A. Enjalbert, P. Jaquet, P. Ruzsniowski, A. Barlier, The analysis of quantitative expression of somatostatin and dopamine receptors in gastroentero-pancreatic tumours opens new therapeutic strategies. *Eur. J. Endocrinol.* **155**, 849–857 (2006)
 21. R. Srirajskanthan, J. Watkins, L. Marelli, K. Khan, M.E. Caplin, Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies. *Neuroendocrinology* **89**, 308–314 (2009)
 22. F. Gatto, L.J. Hofland, The role of somatostatin and dopamine D2 receptors in endocrine tumors. *Endocr. Relat. Cancer* **18**, R233–R251 (2011)
 23. A. Colao, M. Filippella, R. Pivonello, C. Di Somma, A. Faggiano, G. Lombardi, Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. *Eur. J. Endocrinol.* **156**(Suppl 1), S57–S63 (2007)
 24. D. Ferone, F. Gatto, M. Arvigo, E. Resmini, M. Boschetti, C. Teti, D. Esposito, F. Minuto, The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. *J. Mol. Endocrinol.* **42**, 361–370 (2009)
 25. K. Zitzmann, S. Andersen, G. Vlotides, G. Spöttl, S. Zhang, R. Datta, M. Culler, B. Göke, C.J. Auernhammer, The novel somatostatin receptor 2/Dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells. *Neuroendocrinology* **98**, 128–136 (2013)